Drugmakers Moderna and Merck say a messenger-RNA vaccine candidate showed promise in thwarting melanoma when used in combination with another drug, Keytruda, in a mid-stage trial.
Top of the Times: Budweiser struggles to recover
→
The companies said Sunday that nearly 79% of phase 2 trial participants who received the vaccine-drug combination did not see a recurrence of cancer compared to 62% who were cancer-free from using only Keytruda, a Merck therapy.
Moderna, Merck say vaccine-drug combo shows promise against melanoma
→